Please assess the completion status of the following clinical trial:

Trial Title: Pre-Exposure Prophylaxis in YMSM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to independently provide written informed consent;~* Of male gender at birth;~* Between the ages of 18 years and 0 days through 22 years and 364 days at the time of signed informed consent;~* Self-reporting at least one episode of unprotected anal intercourse with a male within the last 12 months at the time of Personal Digital Assistant (PDA) Screening Interview;~* Tests HIV negative at time of screening (using any FDA-approved HIV diagnostic test);~* Willing to provide locator information to study staff;~* Willing to be assigned to any of the three biomedical intervention conditions;~* Does not report intention to relocate out of the study area during the course of the study; and~* Does not have job/other obligations that would require long absences from the area (\> 4 weeks at a time).~Exclusion Criteria:~* Transgender (behavioral intervention not targeted toward this population);~* Presence of serious psychiatric symptoms (e.g., active hallucinations);~* Visibly distraught at the time of consent (e.g., suicidal, homicidal, exhibiting violent behavior);~* Intoxicated or under the influence of alcohol or other drugs at the time of consent;~* Acute or chronic hepatitis B infection (exclude if hepatitis B surface antigen positive);~* Renal dysfunction (Creatinine Clearance \< 75 ml/min); Use Cockcroft-Gault equation: Glomerular Filtration Rate (GFR) = (140-Age in years) x (Weight in kg) / (72 x serum creatinine) for males~* Any history of bone fractures not explained by trauma;~* Confirmed proteinuria (repeated positive \[\> 2+\] urine dipstick), unless explained by orthostatic proteinuria;~* Confirmed glucosuria (repeated positive \[\> 1+\] urine dipstick) in the presence of normal blood glucose (\<120 mg/dL);~* Any Grade 3 toxicity on screening tests/assessments;~* Concurrent participation in an HIV vaccine study or other investigational drug study; or~* Known allergy/sensitivity to the study drug or its components.~* Use of disallowed medications

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 22 Years
- Healthy Volunteers: t

Study Arms:
- FTC/TDF as PrEP (Type: EXPERIMENTAL): Blinded treatment with FTC (Emtricitabine) and TDf (Tenofovir)Pre-Exposure Prophylaxis (PrEP); HIV behavioral intervention
- Placebo Pill Control (Type: PLACEBO_COMPARATOR): Blinded administration of placebo pill; HIV behavioral intervention
- No Pill Control (Type: ACTIVE_COMPARATOR): Subjects receive HIV behavioral intervention but no pill.

Based on this trial design, predict the completion outcome and termination type (if applicable).